Premium
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden
Author(s) -
Yilmaz Musa,
Daver Naval,
Borthakur Gautam,
Kadia Tapan,
DiNardo Courtney,
KanagalShamanna Rashmi,
Loghavi Sanam,
Oran Betul,
Popat Uday R.,
Pierce Sherry,
Jabbour Elias,
Short Nicholas J.,
Issa Ghayas,
Ohanian Maro,
Konopleva Marina,
Patel Keyur,
Kantarjian Hagop,
Ravandi Farhad
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26202
Subject(s) - fms like tyrosine kinase 3 , midostaurin , medicine , myeloid leukemia , npm1 , oncology , transplantation , sorafenib , induction chemotherapy , leukemia , cancer research , mutation , chemotherapy , biology , genetics , gene , chromosome , hepatocellular carcinoma , karyotype